{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:12:48Z","timestamp":1790957568285,"version":"4.1.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This post hoc analysis explored the effects of semaglutide on estimated glomerular filtration (eGFR) slope by baseline glycemic control, blood pressure (BP), body mass index (BMI) and albuminuria status in people with type 2 diabetes and high cardiovascular risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Pooled SUSTAIN 6 (Trial to Evaluate Cardiovascular and Other Long-Term Outcomes With Semaglutide in Subjects With Type 2 Diabetes) and PIONEER 6 (A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes) data were analyzed for change in eGFR slope by baseline hemoglobin A1c (HbA1c) (&amp;lt;8%\/\u22658%; &amp;lt;64\/\u226564\u00a0mmol\/mol), systolic BP (&amp;lt;140\/90\/\u2265140\/90\u00a0mmHg) and BMI (&amp;lt;30\/\u226530\u00a0kg\/m2). SUSTAIN 6 data were analyzed by baseline urinary albumin:creatinine ratio (UACR; &amp;lt;30\/30\u2013300\/&amp;gt;300\u00a0mg\/g).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The estimated absolute treatment differences overall in eGFR slope (95% confidence intervals) favored semaglutide versus placebo in the pooled analysis [0.59 (0.29; 0.89) mL\/min\/1.73 m2\/year] and in SUSTAIN 6 [0.60 (0.24; 0.96) mL\/min\/1.73 m2\/year]; the absolute benefit was consistent across all HbA1c, BP, BMI and UACR subgroups (all P-interaction &amp;gt;.5).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>A clinically meaningful reduction in risk of chronic kidney disease progression was observed with semaglutide versus placebo regardless of HbA1c, BP, BMI, and UACR levels.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfae150","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T16:46:44Z","timestamp":1719852404000},"page":"352-359","source":"Crossref","is-referenced-by-count":20,"title":["Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6"],"prefix":"10.1093","volume":"40","author":[{"given":"Ellen M","family":"Apperloo","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy & Pharmacology, University of Groningen, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z I","family":"Cherney","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University Health Network and University of Toronto , Toronto, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja Birk","family":"Kuhlman","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes F E","family":"Mann","sequence":"additional","affiliation":[{"name":"KfH Kidney Center , Munich ,","place":["Germany"]},{"name":"Dept of Nephrology & Hypertension, Friedrich Alexander University of Erlangen , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-4294","authenticated-orcid":false,"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"Steno Diabetes Centre , Copenhagen ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2235-0103","authenticated-orcid":false,"given":"Katherine R","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Providence Inland Northwest Health, University of Washington School of Medicine , Spokane ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blaz","family":"Vrhnjak","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J L","family":"Heerspink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy & Pharmacology, University of Groningen, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]},{"name":"The George Institute for Global Health , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"key":"2025020415120424300_bib1","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","article-title":"Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int"},{"key":"2025020415120424300_bib2","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.2337\/dc22-S010","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes\u20142022","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","journal-title":"Diabetes Care"},{"key":"2025020415120424300_bib3","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","article-title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo","volume":"103","author":"Tuttle","year":"2023","journal-title":"Kidney Int"},{"key":"2025020415120424300_bib4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"2025020415120424300_bib5","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2025020415120424300_bib6","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1016\/j.ekir.2022.07.167","article-title":"Hemoglobin A1c reduction with the GLP-1 receptor agonist semaglutide is independent of baseline eGFR: post hoc analysis of the SUSTAIN and PIONEER programs","volume":"7","author":"Cherney","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2025020415120424300_bib7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/dom.13553","article-title":"Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: rationale, design and patient baseline characteristics for the PIONEER 6 trial","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2025020415120424300_bib8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"2025020415120424300_bib9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2025020415120424300_bib10","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.2337\/dc22-S006","article-title":"6. Glycemic targets: standards of medical care in diabetes\u20142022","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","journal-title":"Diabetes Care"},{"key":"2025020415120424300_bib11","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"2025020415120424300_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate endpoint for kidney failure","author":"Inker","year":"2023","journal-title":"Nat Med"},{"key":"2025020415120424300_bib13","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025020415120424300_bib14","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1111\/dom.14443","article-title":"Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis","volume":"23","author":"Mann","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2025020415120424300_bib15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.23876\/j.krcp.22.001","article-title":"GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions","volume":"41","author":"Yu","year":"2022","journal-title":"Kidney Res Clin Pract"},{"key":"2025020415120424300_bib16","author":"REMODEL trial (NCT04865770) [Online]."},{"key":"2025020415120424300_bib17","author":"SMART trial (NCT04889183) [Online]."},{"key":"2025020415120424300_bib18","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4\u00a0mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfae150\/58606358\/gfae150.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/2\/352\/58606358\/gfae150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/2\/352\/58606358\/gfae150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T15:12:17Z","timestamp":1738681937000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/2\/352\/7704453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,7,2]]},"published-print":{"date-parts":[[2025,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfae150","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,7,2]]}}}